CLINICAL TRIALS PROFILE FOR PF-05221304

Clinical Trials for PF-05221304

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02871037 ↗	Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects	Completed	Pfizer	Phase 1	The current study is the first clinical trial proposed with PF-05221304. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) following administration of single and repeated doses of PF-05221304 to healthy adult subjects. The study may also evaluate effect of food on PK of PF-05221304.
NCT03248882 ↗	Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)	Completed	Pfizer	Phase 2	Phase 2a, dose-ranging Study with PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
NCT03309202 ↗	Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment	Completed	Pfizer	Phase 1	Hepatic impairment PK study
NCT03448172 ↗	Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects	Completed	Pfizer	Phase 1	The purpose of the study is to characterize the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of [14C]PF-05221304 in Healthy Adult Male Subjects
NCT03534648 ↗	Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects	Completed	Pfizer	Phase 1	Drug drug interaction study between PF-05221304 and PF-06865571
NCT03597217 ↗	A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults	Completed	Pfizer	Phase 1	The current study is designed to evaluate the safety, tolerability and pharmacokinetics of PF-05221304 in healthy Japanese adult subjects following single and multiple dose administration.

Clinical Trial Conditions for PF-05221304

Condition Name

Condition Name
Intervention	Trials
Healthy	4
Nonalcoholic Fatty Liver Disease	3
Nonalcoholic Steatohepatitis	2
Normal Healthy	1

Condition MeSH

Condition MeSH
Intervention	Trials
Liver Diseases	6
Non-alcoholic Fatty Liver Disease	5
Fatty Liver	5
Fibrosis	1

Clinical Trial Locations for PF-05221304

Trials by Country

Trials by Country
Location	Trials
United States	71
Canada	15
Japan	12
China	10
India	6

Trials by US State

Trials by US State
Location	Trials
Florida	5
Virginia	4
Texas	4
Ohio	4
New York	4

Clinical Trial Progress for PF-05221304

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2	4
Phase 1	7

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	8
Recruiting	2
Withdrawn	1

Clinical Trial Sponsors for PF-05221304

Sponsor Name

Sponsor Name
Sponsor	Trials
Pfizer	11
Columbia University	1
Henry N. Ginsberg	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	11
Other	2